Speaker(s): 

Paul Blankemeyer, GWV Pharmacy Intern - has nothing to disclose 

Carlie Kozlowich, GWV Pharmacy Intern - has nothing to disclose 

Jessica Bohner, GMCM Pharmacy Intern - has nothing to disclose

Moderator(s): 

Sarah Hale, Pharm.D., BCPPS. Director of Pharmacy, Geisinger-has nothing to disclose 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Identify the non-inferior short-term duration oral antibiotic options for the treatment of rifampin-resistant, fluoroquinolone-susceptible tuberculosis.

• Compare and contrast the advantages and disadvantages between the standard therapy group and experimental groups.

• Identify gaps in current medical knowledge regarding cardiovascular risk and gender-affirming estrogen therapy in transgender, nonbinary and gender diverse populations.

• Describe the future study types and relevant endpoints to fill such knowledge gaps.

• Recognize the significance of novel antibiotics in filling the gaps in current antibiotic treatment options for uncomplicated urinary tract infections (UTIs).

• Design a treatment plan using gepotidacin for treatment of uncomplicated UTI.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Sarah F. Hale, PharmD, Brain Simpkins, PharmD, Jessica Milheim, CPhT, and Tiffany Tang, PharmD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None